Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,502.00GBp
13 Jul 2018
Change (% chg)

68.00 (+1.25%)
Prev Close
5,434.00
Open
5,500.00
Day's High
5,536.00
Day's Low
5,479.00
Volume
2,135,837
Avg. Vol
1,939,974
52-wk High
5,536.00
52-wk Low
4,260.00

Select another date:

Fri, Jul 6 2018

Photo

Hitting cancer early: AstraZeneca's bid to outmaneuver rivals

LONDON AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit.

Hitting cancer early - AstraZeneca's bid to outmanoeuvre rivals

LONDON AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit.

FOCUS-Hitting cancer early: AstraZeneca's bid to outmanoeuvre rivals

* Drugmaker gets its mojo back a year after cancer study flop

AstraZeneca, Merck eye $1 billion boost from cancer drug success

LONDON AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

AstraZeneca, Merck eye $1 billion boost from cancer drug success

LONDON AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

UPDATE 1-AstraZeneca, Merck eye $1 bln boost from cancer drug success

* Puts drug ahead of competition in PARP medicine race (Adds analyst reaction, sales forecasts)

AstraZeneca, Merck eye wider cancer drug use after study success

LONDON, June 27 AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

Lilly-AstraZeneca latest to abandon Alzheimer's drug trials

Eli Lilly and Co and AstraZeneca Plc said on Tuesday they would discontinue late-stage trials testing their Alzheimer's treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.

Lilly-AstraZeneca latest to abandon Alzheimer's drug trials

June 12 Eli Lilly and Co and AstraZeneca Plc said on Tuesday they would discontinue late-stage trials testing their Alzheimer's treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

AstraZeneca's first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Select another date: